Methicillin-resistant Staphylococcus aureus Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations and Other Developments - ResearchAndMarkets.com

DUBLIN--()--The "Methicillin-resistant Staphylococcus aureus Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.

The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different stages of development.

According to the research findings, a majority of the drug candidates for the treatment of MRSA are being developed to be administered by the intravenous route which offers good bioavailability and is considered to be more effective at the target site.

The players in the MRSA therapeutics pipeline have been receiving increasing support from various organizations in the form of research funding. For instance, Microbiotix Inc received Phase l grants from SBIR for Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus for a term of two years in February 2012.

It has been observed that most of the companies are developing drug candidates with novel mechanism of action. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development.

For instance, GlaxoSmithKline plc is developing a Phase II drug candidate, GSK 2140944 or Gepotidacin. It is an intravenous, synthetic, Type II topoisomerase inhibitor. If GSK2140944 hits the market, it would be the first topoisomerase inhibitor for gram-negative infections.

Savara Pharma's AeroVanc is the first inhaled antibiotic being developed and is in the Phase III stage of clinical trial and has received $5 million fund from Nonprofit Cystic Fibrosis Foundation. If the drug receives the approval, it would be the first inhaled antibiotic to be developed for the treatment of MRSA.

Key Players Featured

  • GlaxoSmithKline plc
  • Crystal Genomics Inc.
  • Innovation Pharmaceuticals Inc.

Key Topics Covered

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. MRSA Infections Therapeutics Pipeline Analysis by Phase (2018)

6. Clinical Trials Review

7. Competitive Landscape

8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/jzdbrw/methicillinresist?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Clinical Trials, Antibiotics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Clinical Trials, Antibiotics